CMS has finalized its rejection of Epigenomics' blood-based colorectal cancer screening test, depriving the company of the chance to sell the liquid biopsy for Medicare beneficiaries. Epigenomics is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results